Hormonal
GLP-1 receptor agonists (specifically semaglutide 2.4 mg and tirzepatide) produce significant weight loss (14.9-20.9%) and improve cardiometabolic risk factors in adults with overweight or obesity, regardless of diabetes status.
If you have overweight or obesity, GLP-1 agonists like semaglutide or tirzepatide are highly effective for weight loss, producing 15-21% body weight reduction in clinical trials. These benefits occur even if you do not have diabetes. Discuss these options with your provider, keeping in mind that cost and access may be barriers, but coverage is expanding for cardiovascular risk reduction.
In STEP 1, participants without diabetes achieved a mean weight reduction of 14.9% at 68 weeks compared to 2.4% with placebo (p < 0.001)... At the lowest dose (5 mg weekly), participants lost an average of 15% of their body weight over 72 weeks, while participants who received the highest dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks compared to 3.1% with placebo
Why this rating
Based on large-scale, randomized, placebo-controlled trials (STEP 1, SURMOUNT-1) with statistically significant results.
Source
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
Lucianne West et al. · Reviews in Cardiovascular Medicine · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →